The content on this site is intended for healthcare professionals only
Dr Luis Paz-Ares summarises the DELPHI-308 phase 1 trial of subcutaneous talquetamab for extensive-stage small cell lung cancer.
The study details safety, dosing, and preliminary efficacy, highlighting a 30% response rate and manageable side effects.
Dr Paz-Ares says that the findings suggest talquetamab's significant potential in treating this challenging cancer.
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC
